RAP-103
Pre-clinical- Indications
- Opioid Use Disorder, Persistent Post-Surgical Pain, Dementia
Company intelligence / Profile preview
Creative Bio-Peptides Inc.
San Francisco, California, United Statescreativebiopeptides.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing RAP-103 (R103), a multi-chemokine receptor antagonist that has shown promise in protecting synapses in dementia models, inhibiting opioid-derived dependence, and providing post-surgical pain relief in preclinical studies[1][8]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Oral peptide immunotherapiesReceptor-active peptides (RAPs)Chemokine receptor antagonists
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Creative Bio-Peptides Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Creative Bio-Peptides Inc..